| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/03/2008 | WO2008077404A1 Substituted acetophenones useful as pde4 inhibitors |
| 07/03/2008 | WO2008077311A1 Hepatopoietin and use thereof |
| 07/03/2008 | WO2008077305A1 Quinoline compounds, intermediates, prepartion methods and uses thereof |
| 07/03/2008 | WO2008077247A1 Coatings for implantable medical devices comprising cholesterol |
| 07/03/2008 | WO2008077241A1 Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections |
| 07/03/2008 | WO2008077234A1 Synergistic effects of c3, cyclic amp and ciliary neurotrophic factor on neuronal survival and axonal regeneration |
| 07/03/2008 | WO2008077188A1 Bicyclic pyrimidinones and uses thereof |
| 07/03/2008 | WO2008077170A2 Benzothioamides, and use thereof for relaxing smooth muscles |
| 07/03/2008 | WO2008061208A3 Arylsulfonamide compounds |
| 07/03/2008 | WO2008061208A2 Arylsulfonamide compounds |
| 07/03/2008 | WO2008060927A3 Hepatitis c virus inhibitors |
| 07/03/2008 | WO2008060927A2 Hepatitis c virus inhibitors |
| 07/03/2008 | WO2008058033A3 Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis |
| 07/03/2008 | WO2008057575A3 Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| 07/03/2008 | WO2008057534A3 Methods and compositions for organ protection |
| 07/03/2008 | WO2008057511A3 Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof |
| 07/03/2008 | WO2008057456A3 Methods of using saha and bortezomib for treating multiple myeloma |
| 07/03/2008 | WO2008057442A3 Eyelid scrub composition |
| 07/03/2008 | WO2008057291A3 Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof |
| 07/03/2008 | WO2008056059A3 4-azasterol derivatives, methods for the synthesis thereof and use of same as drugs |
| 07/03/2008 | WO2008055092A3 Use of enoxaparin sodium for treating patients with acute ischemic stroke |
| 07/03/2008 | WO2008054594A3 Method for controlling angiogenesis in animals |
| 07/03/2008 | WO2008054540A9 Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| 07/03/2008 | WO2008052709A3 Monoesters of estrogens with conjugated linoleic acid and uses thereof |
| 07/03/2008 | WO2008052671A3 Combination therapy of substituted oxazolidinones |
| 07/03/2008 | WO2008051942A3 Farnesoid x receptor agonists |
| 07/03/2008 | WO2008051493A3 Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| 07/03/2008 | WO2008051186A3 Nanoemulsion containing compositions having ant i -inflammatory activity |
| 07/03/2008 | WO2008049919A3 Rho kinase inhibitors |
| 07/03/2008 | WO2008049401A3 Nail varnish for cosmetic and medical applications |
| 07/03/2008 | WO2008047061A3 Cosmetic oral and/or parenteral use of glucosamine optionally in combination with at least one polyphenol compound, and corresponding composition |
| 07/03/2008 | WO2008046038A9 Intranasal therapeutics for neuroprotection |
| 07/03/2008 | WO2008043533A3 Acyl aminoimidazoles and acyl aminothiazoles |
| 07/03/2008 | WO2008042619A3 Self-preserved aqueous pharmaceutical compositions |
| 07/03/2008 | WO2008042399A9 Method for treatment of macular degeneration |
| 07/03/2008 | WO2008041184A3 Muscarinic receptor antagonists |
| 07/03/2008 | WO2008041088A3 N-hydroxy benzamides with antitumor activity |
| 07/03/2008 | WO2008039406A3 Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| 07/03/2008 | WO2008037557A3 Rapidly solubilising formulation of non-steroidal anti-inflammatory drugs |
| 07/03/2008 | WO2008036980B1 Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof |
| 07/03/2008 | WO2008034796A3 Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors |
| 07/03/2008 | WO2008031048A3 Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes |
| 07/03/2008 | WO2008031034A3 Therapeutic compounds for diseases and disorders |
| 07/03/2008 | WO2008030744A3 Inhibitors of c-met and uses thereof |
| 07/03/2008 | WO2008030209A3 Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor |
| 07/03/2008 | WO2008030108A8 Animal production |
| 07/03/2008 | WO2008027854A3 Pharmaceutical compositions comprising hgh for oral delivery |
| 07/03/2008 | WO2008027013A3 Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer |
| 07/03/2008 | WO2008024980A3 Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives |
| 07/03/2008 | WO2008024456A3 Substituted acylanilides and methods of use thereof |
| 07/03/2008 | WO2008024151A3 Salts and co-crystals of pyrazolopyrimidine compounds, compositions thereof and methods for their production and use |
| 07/03/2008 | WO2008023362A3 Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer |
| 07/03/2008 | WO2008022267A3 Combination treatment for metabolic disorders |
| 07/03/2008 | WO2008021242A3 Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof |
| 07/03/2008 | WO2008019115A3 Formulations for parenteral delivery of compounds and uses thereof |
| 07/03/2008 | WO2008019030A3 Modified azole compounds as antiinfective agents |
| 07/03/2008 | WO2008014307A3 Inhibitors of undecaprenyl pyrophosphate synthase |
| 07/03/2008 | WO2008013743A3 Methods for inhibiting reperfusion injury |
| 07/03/2008 | WO2008003637B1 Isolation and use of amine salts of mycophenolic acid |
| 07/03/2008 | WO2008003484A3 Agent containing chrysin and cholic acid for reducing weight, accelerating lipid catabolism, and/or restricting calories |
| 07/03/2008 | WO2008002956A3 Thiazoline and oxazoline derivatives and their methods of use |
| 07/03/2008 | WO2008002676A9 Biaryl compositions and methods for modulating a kinase cascade |
| 07/03/2008 | WO2008002596A3 Adenosine a2a receptor antagonists |
| 07/03/2008 | WO2007149728A3 Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
| 07/03/2008 | WO2007147613A3 Combinations comprising staurosprorines |
| 07/03/2008 | WO2007143434A3 Indazole and isoindole derivatives as glucokinase activating agents |
| 07/03/2008 | WO2007140299A3 Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals |
| 07/03/2008 | WO2007139939A3 Methods and compositions using immunomodulatory compounds in combination therapy |
| 07/03/2008 | WO2007137417A8 Heterocyclic compounds as calcium channel blockers |
| 07/03/2008 | WO2007137066A3 HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME |
| 07/03/2008 | WO2007136653A3 Use of a rar antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects |
| 07/03/2008 | WO2007132269A3 Dub3 as a cancer therapy target |
| 07/03/2008 | WO2007124383A3 1,1'-binaphthyl-based inhibitors of nad+-dependent deacetylase activity and sir2-family members |
| 07/03/2008 | WO2007123686A3 Dpp inhibitors and uses thereof |
| 07/03/2008 | WO2007119214A3 Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| 07/03/2008 | WO2007118151A3 Spirocyclic heterocyclic derivatives and methods of their use |
| 07/03/2008 | WO2007114902A3 Alkylthiobenzylpiperidine compounds |
| 07/03/2008 | WO2007113322A3 Substituted 5-hetarylpyrimidines for combating plant pathogenic fungi and cancers |
| 07/03/2008 | WO2007111720A8 Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| 07/03/2008 | WO2007101357A3 Hair growth agent for the treatment of human keratin fibers, and method for the production thereof |
| 07/03/2008 | WO2007100652A3 Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| 07/03/2008 | WO2007092433A3 Osteoporosis associated markers and methods of use thereof |
| 07/03/2008 | WO2007079422A3 Enhancement of urogenital function |
| 07/03/2008 | WO2007070355A3 Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes |
| 07/03/2008 | WO2007065173A3 Compositions and methods for increasing production of recombinant gamma-carboxylated proteins |
| 07/03/2008 | WO2007054783A3 Compositions and methods for treating thrombocytopenia |
| 07/03/2008 | WO2007047486B1 Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites |
| 07/03/2008 | WO2007039112A8 Novel phloroglucinol derivatives having selectin ligand activity |
| 07/03/2008 | WO2006134494A3 Anti-connexin compounds and therapeutic uses thereof |
| 07/03/2008 | WO2006101950A3 Pxr agonists for cardiovascular disease |
| 07/03/2008 | WO2003068170A3 Enzyme treatment of foodstuffs for celiac sprue |
| 07/03/2008 | US20080161908 Apparatus and Method for Delivery of Mitomycin Through an Eluting Biocompatible Implantable Medical Device |
| 07/03/2008 | US20080161907 Stent coated with a sustained-release drug delivery and method for use thereof |
| 07/03/2008 | US20080161782 Micropore delivery of active substances |
| 07/03/2008 | US20080161607 Solution of sertraline is seeded with some crystals of polymorphic form II and hydrogen chloride gas; salt formation |
| 07/03/2008 | US20080161577 Muscarinic receptor antagonists; longer duration of action; side effect reduction; high potency; chronic obstructive pulmonary disease; asthma; inhalation; 2-[(S)-1-(8-Methylaminooctyl)pyrrolidin-3-yl]-2,2-diphenylacetamide |
| 07/03/2008 | US20080161562 2-(6-Chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)-benzonitrile |
| 07/03/2008 | US20080161551 Carrageenan Based Antimicrobial Compositions |
| 07/03/2008 | US20080161426 p53 Inhibitors and Therapeutic Use of the Same |
| 07/03/2008 | US20080161419 Selective antagonistic compounds 5-HT2B and 5-HT7 receptors; reduced side effects |